… compared with erlotinib, gefitinib is more suitable for treating advanced NSCLC in East
Asian patients. Further large-scale, well-designed randomized controlled trials are warranted to …

… Liang et al indicated that erlotinib, gefitinib, and afatinib have equivalent efficacy. This
meta-analysis included twelve phase III global clinical trials involving 1812 NSCLC patients with …

… In conclusion, this study demonstrates that, in a clinically selected patient population, …
failed platinum-based chemotherapy, gefitinib/erlotinib and afatinib monotherapy improves PFS …

… , there is no relative OS advantage with frontline gefitinib or erlotinib vs chemotherapy in
EGFR-mutated … Multiple randomized controlled trials (RCTs) have demonstrated improvement in …

… This is also the first randomized clinical trial in the entire cancer prevention field to utilize
molecular risk assessment as a core selection strategy, thus attempting to develop a …

… controlled trials could be identified. Secondly, the small sample size of the included studies
… based on phase II trials, and more phase III randomized controlled trials are needed. Thirdly…

… EGFR TKIs in gefitinib- and erlotinib-sensitive and -resistant preclinical models [6, 7]. In a …
comparison in randomized clinical trials is needed to address this important clinical issue. …

… A search of ClinicalTrials.gov showed that several randomised trials comparing EGFR tyrosine
kinase inhibitors are ongoing, including: a phase 2 trial comparing erlotinib and gefitinib (…

… Our purpose of this study is to investigate how afatinib is used in real-world practice, and
whether it leads to different clinical outcomes compared with gefitinib or erlotinib. …

… randomized controlled trial to directly compare lower dose erlotinib with standard dose gefitinib
… Therefore, in Stage IV EGFR mutated NSCLC, this study showed that erlotinib 100 mg/d …